Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology
AUTOR(ES)
Li, MJ
FONTE
Pulsus Group Inc
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2780895Documentos Relacionados
- Collaborative care model improves self-care ability, quality of life and cardiac function of patients with chronic heart failure
- Aerobic exercise improves the inflammatory profile correlated with cardiac remodeling and function in chronic heart failure rats
- Chronic treatment with Carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure
- Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study
- High Level of Lipoprotein(a) as Predictor for Recurrent Heart Failure in Patients with Chronic Heart Failure: a Cohort Study